Vascular cell adhesion protein 1 and Intercellular adhesion molecule 1 (VCAM-1 and ICAM-1)

Vascular cell adhesion protein 1 (VCAM-1) and Intercellular adhesion molecule 1 (ICAM-1) are critical transmembrane glycoproteins of the immunoglobulin superfamily that facilitate the recruitment of T-lymphocytes to sites of inflammation (Springer, 1994, PMID: 7915818). Expressed primarily on activated endothelial cells, VCAM-1 binds to the integrin alpha-4 beta-1 (VLA-4) on leukocytes, while ICAM-1 serves as a ligand for integrin alpha-L beta-2 (LFA-1) and alpha-M beta-2 (Mac-1) (Muller, 2011, PMID: 21594131). These interactions are essential for the multi-step process of leukocyte rolling, firm adhesion, and diapedesis across the blood vessel wall. In pathological states, over-expression of these molecules leads to excessive T-cell infiltration, contributing to the progression of autoimmune diseases like multiple sclerosis and Crohn's disease, as well as atherosclerosis (Yusuf-Makagiansar et al., 2002, PMID: 11849201). Therapeutic agents such as natalizumab and vedolizumab target these pathways by blocking the integrin-ligand interaction, thereby reducing tissue inflammation (Feagan et al., 2013, PMID: 23964932). However, systemic blockade of these adhesion pathways can lead to significant safety concerns, most notably the risk of progressive multifocal leukoencephalopathy (PML) due to impaired CNS immune surveillance (Kleinschmidt-DeMasters & Tyler, 2005, PMID: 15951574).

Other names

CD106CD54Vascular cell adhesion molecule 1Intercellular adhesion molecule 1VLA-4 ligandsLFA-1 ligands

Inhibition of leukocyte adhesion and transendothelial migration by blocking the interaction between integrins (such as VLA-4 and LFA-1) and their endothelial ligands (VCAM-1 and ICAM-1).